Standing Order
Eli Lilly and Company

Dashboard

Eli Lilly and Company

LLYNYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$1.0T
Price$1,150.9952w $625.65 – $1,280.34
Conviction5/ 5
Revenue (TTM)$79.7B
Revenue growth YoY+49.6%
P/E (trailing)38.4
Gross margin83.4%
Operating margin49.7%
Net margin33.5%
52w price change+54.1%
Next earningsOct 29, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 23
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 4 trial of selpercatinib in RET-altered cancers in India; status not yet recruiting.

  • Sep 23
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 2 master protocol study NCT05986292 in chronic pain updated to recruiting status.

  • Sep 23
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1/2 trial of Pirtobrutinib in Immune Thrombocytopenia (NCT06721013, recruiting).

  • Sep 23
    Trial initiationClinicalTrials.gov

    Phase 1 trial of tirzepatide in type 1 diabetes with overweight or obesity now recruiting.

  • Sep 23
    Trial readoutClinicalTrials.gov

    Eli Lilly terminates Phase 2 trial NCT06220669 of LY3541860 in relapsing multiple sclerosis (status updated 2026-09-23).

  • Sep 23
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1 trial of Abemaciclib (LY2835219) in healthy participants (NCT07818967), recruiting status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 2 trial NCT07415044 for LY4268989 in ulcerative colitis updated to recruiting status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 3 master protocol trial NCT07165028 (SYNERGY-Outcomes) evaluating multiple agents in MASLD; recruiting status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 3 trial (NCT07213804) initiated for Sofetabart Mipitecan in platinum-resistant/sensitive ovarian cancer; recruiting.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly phase 3 trial NCT03773965 of baricitinib in juvenile idiopathic arthritis (ages 1-<18) updated to recruiting status.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07241390 of orforglipron for CV outcomes in ASCVD/CKD patients begins recruiting.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07808073 of LY4329090 in obesity/overweight, status NOT_YET_RECRUITING

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 3 trial of orforglipron (LY3502970) in T2D patients observing Ramadan fasting now recruiting (NCT07613307).

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07222137 of baricitinib initiated for delaying stage 3 type 1 diabetes; status recruiting.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 4 trial NCT07218341 of Pirtobrutinib (LY3527727) in CLL/SLL; recruiting status as of 2026-09-22.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1 trial NCT07213791 of LY4337713 in FAP-positive solid tumors; status recruiting.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 2 trial NCT07287098 of Imlunestrant (LY3484356) in premenopausal ER+ HER2- early breast cancer status updated to RECRUITING.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Phase 2 trial NCT07483099 of LY4395089 + mirikizumab vs mirikizumab alone in Crohn's disease now recruiting.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 2 trial NCT07533019 of LY4005130 for non-segmental vitiligo, status recruiting as of 2026-09-22.

  • Sep 22
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 3 trial of Brenipatide in Alcohol Use Disorder (NCT07219953, recruiting).

Not financial advice — research and opinion only. Disclosures